reduced intensity conditioning; nonmyeloablative stem cell transplantation (NST); high-risk patients; leukemia; hematologic malignancies Allogeneic stem cell transplantation (SCT) from a fully matched donor is the treatment of choice for a growing number of clinical indications. In the past, age above 60 years was considered a contraindication to SCT due to anticipated high procedure-related toxicity and mortality. However, the recent progress in understanding the important role of alloreactive donor lymphocytes and the clinical application of reduced intensity conditioning (RIC) has resulted in successful nonmyeloablative stem cell transplantation (NST) for a larger number of patients, and suggest that some of these dogmatic contraindications need to be reconsidered. One of the changes is the introduction of allogeneic transplant in elderly patients. Nonetheless, data on the results and complications of SCT in this age group are lacking. The present report summarizes our cumulative experience that documents the feasibility of SCT in a cohort of 17 patients.
Patients and methods
A total of 17 consecutive elderly (above 60 years old) patients, 60-67 (median 62.5) years, 12 males and five females, with hematologic malignancies are reported. Indications for transplantation and disease status are shown in Table 1 . The median donor age was 58 (range 30-73). The median Karnovsky performance status score was 90 (range 60-100). Patients were referred to the Hadassah Hospital for SCT between September 1996 and June 2003. Each participant signed an approved informed consent form. Patients were included only if they had an ECOG PS p2, creatinine o2.0 mg/dl, ejection fraction 440%, DLCO 450% of that predicted, serum bilirubin o3 g/dl, elevated GPT or GOT o3 Â normal values.
In all, 12 patients were transplanted from HLA-A, B, C and high-resolution DR fully matched siblings; three patients received stem cell graft from fully matched unrelated donor (MUD) nonreactive in mixed lymphocyte culture and two patients were transplanted from partially mismatched siblings.
Pre-transplant conditioning consisted mostly of fludarabine and busulfan with few variations, as indicated in Table 2 . Donors were injected subcutaneously with granulocyte-colony-stimulating factor (G-Neupogen & , 5 mg/kg twice daily for 5 days) and mobilized peripheral blood stem cells were collected on days 5 and 6. The details of the mobilized inoculums are presented in Table 3 .
Prior to transplantation, all patients received trimethoprim/sulfamethoxazole (10 mg/kg/day trimethoprim) on days À8 to À2, acyclovir (500 mg/m 2 Â 3/day) from days À8 until day þ 100, and allopurinol (300 mg/day) on days À8 to À1. Administration of trimethoprim/sulfamethoxazole (twice weekly) was reinstituted after recovery from neutropenia as a preventive measure against pneumocystis carinii infection.
Graft-versus-host disease (GVHD) prophylaxis consisted of single-drug low-dose, short-term cyclosporine (CSA) 3 mg/kg i.v. daily in two divided doses starting on day À4. Once the patients were mobile, CSA was administered orally. CSA dosage was tapered during the second or third month post transplant, according to chimeric status and evidence of GVHD. In the patients that had partially mismatched donors, T-cell depletion was done using positive stem cell selection (using CD34 immunomagnetic beads in one patient and AC133 immunomagnetic bead in another patient).
Neutropenic patients with culture-negative fever received a combination of gentamicin, cefazolin and mezlocillin, as a first-line antibiotic protocol. Persisting fever was treated with amikacin and tazocin as a second-line protocol, while meropenem and vancomycin were used as the third line protocol. In cases of persistent fever not responding to antibiotic therapy within 5 days, amphotericin B (1 mg/kg every other day) was added until the neutropenia resolved.
Starting on day À8, patients were monitored with a DNA-PCR test and later during the study period pp65 1 Immediately upon the appearance of signs and symptoms of GVHD, i.v. methylprednisolone (2 mg/kg) and CSA were administered.
In order to assess engraftment, the degree of chimerism, minimal residual disease and early relapse, patients were monitored at regular intervals by cytogenetic analysis, and by donor and host-specific DNA markers, using male and female amelogenine gene PCR bands, 2 and by VNTR-PCR assay. 3 Study end points and statistical analysis data were collected by comprehensive chart review. The major outcomes were transplant-related morbidity and mortality, survival, non-relapse mortality (NRM), engraftment, disease response, relapse, and incidence/severity of GVHD. Overall survival (OS) was measured from transplantation until death from any cause. Transplant-related morbidity and mortality was defined as morbidity or mortality due to any cause other than disease progression within 100 days of transplantation. Major and transplant-related morbidity were defined as life-threatening and not life-threatening events, respectively. NRM was defined as mortality due to any cause other than disease progression within 1 year of transplantation. Data analysis was done using Microsoft Excel.
Results
A total of 17 patients underwent 18 allogeneic transplant procedures (patient UPN 1018 had two transplants 4.5 years apart).
Engraftment
All patients displayed evidence of tri-lineage engraftment and none exhibited immune-mediated rejection. One patient (UPN 1256) required an addition of donor bone marrow cells given on day þ 19 without manipulation, engraftment was noted 8 days later.
Time to recovery of absolute neutrophil count (ANC) X0.5 Â 10 9 and X1.0 Â 10 9 /l was 9-27 (median 14) days and 12-31 (median 15) days, respectively. The time interval to platelet recovery (X20 and X50 Â 10 9 /l) ranged from 3 to 96 (median 11) days and from 8 to 65 (median 13.5) days, respectively. The median number of packed red cell consumption was 5.5 units (range 0-40) and median platelet consumption (both single and random donors) was 11 units (range 0-50).
Transplant-related morbidity and mortality
Major transplant-related complications (not leading to death) occurred in 6/18 (33.3%) episodes and included: acute renal failure (3/18 episodes), one of which necessitated peritoneal dialysis, nonischemic paroxysmal atrial fibrillation (2/18 episodes) treated with anti-arrhythmic medications and cardiac electroversion, CNS bleeding (2/18 episodes), hemorrhagic cystitis (1/18 episodes), conservatively treated typhlitis (1/18 episodes) and gastrointestinal bleeding (1/18 episodes). Minor transplant-related morbidity included hepatic veno-occlusive disease (VOD) occurring only in 3/18 procedures. None of the VOD episodes was a cause of any further complication and subsided with conventional treatment. Fever was noted in most of the procedures (15/18, 83%), with a median of one febrile episode (range 0-3) and median 8 febrile days (range 0-23 days).
Oral mucositis was common and most of the patients (11/18 procedures -61.1%) required supplemental parenteral nutrition (median 12 day, range 0-35); however, during seven procedures patients were maintained on normal oral intake.
Transplant-related mortality occurred in 6/18 (33.3%) episodes. Three of the six were patients who had major transplant-related morbidity. NRM occurred in 8/17 episodes (47%). In all, 12 of the 17 patients (12/18 episodes) were discharged home for a continuing outpatient treatment.
Overall survival
In spite of the patients' old age and advanced stage of disease (Table 1) , 5/17 (29%) patients survived (median follow-up 13 months, range 10-55 months). All patients who survived are currently in CR, including one (UPN 1415) who relapsed but responded to chemotherapy and DLI and is now in CR 55 months post transplant. The median follow-up of patients who did not experience transplant-related mortality was 11 months (range 4.9-71.5 months). Causes of death included transplant-related mortality in 6/18 (33.3%), including: hemorrhagic shock, GVHD, CNS bleeding, sepsis, respiratory failure and multi-organ failure (one patient each). Non-transplantrelated mortality included relapse (2/18, 2.6 and 5.6 months post transplant), chronic GVHD and its complications (2/ 18, 5 months post transplant for both) and cerebrovascular event (1/18, 61.3 months post transplant). One patient (UPN 1188) died more than 100 days post transplant, data relating to the cause of her death are lacking. The median time to death was 2.3 months (range 0.5-70.9 months).
Incidence and severity of GVHD
Acute GVHD (Xgrade I) occurred in 10/18 episodes; three of those patients developed grade III-IV acute GVHD. In six episodes acute GVHD progressed to chronic GVHD. As mentioned above, GVHD-related mortality occurred in two patients.
Discussion
While advances in standards of living, medicine and technology have resulted in a higher proportion of elderly individuals in the population, there has been a call for greater allocation of resources to prevent disability and maintain the quality of life. 4 Furthermore, the prevalence of various hematological malignancies such as acute myeloid leukemia, chronic myeloid leukemia, lymphoma, multiple myeloma and myelodysplastic syndromes increases with age, and the response to treatment is poorer than in young patients. Whereas SCT may provide a cure for some of these patients, conventional myeloablative SCT is a high-risk procedure even for young patients in excellent general condition, hence most dangerous and usually not applicable for elderly patients. Our previous reports as well as data obtained from other transplant centers confirm that procedure-related toxicity and mortality may be reduced by using nonmyeloablative or reduced intensity conditioning prior to transplantation of allogeneic stem cells, while retaining the antitumor effects of alloreactive donor lymphocytes. 5, 6, [8] [9] [10] Nevertheless, data regarding SCTrelated toxicity in elderly patients are scarce and focus more concentrated on autologous [11] [12] [13] [14] [15] than allogeneic SCT. 10, [16] [17] [18] In this report, we present our cumulative experience in elderly patients (X60 years) undergoing allogeneic SCT with RIC for hematological malignancies. We have shown that, in view of the patients' advanced age and complicated medical history (Table 1) , transplant-related mortality was acceptable (33.3%). Most of the patients (12/18 transplant procedures) were discharged for a continuing outpatient follow-up. Also noteworthy is the fact that, except for one patient, all other patients were referred for SCT with active disease and after massive prior treatment, and suggests that the overall survival of 29% (5/17) can be considered satisfactory for such a group of high-risk patients. We assume that these results can be further improved if goodrisk elderly patients are referred for allogeneic SCT. A recent article by Wong et al 18 in a slightly younger patient group (455 years, median 59 years) also demonstrated the feasibility of allo-SCT with a TRM of 41.4% and NRM of 55%. In their series, 7/29 patients (24.1%) were either in CR or had CML CP, whereas we had only one patient in CR (5.6%) and no CML CP. Our series also included two patients transplanted using partially mismatched sibling donors.
Interestingly, it is notable that the ages of donor, and recipients of solid organs have also increased in the last decade. 19 In parallel, the upper age limit for other high-risk procedures such as aortic valve replacement, coronary artery bypass surgery, etc have also increased. 20, 21 Our results demonstrate that RIC may be suitable for elderly individuals and patients with other risk factors such as poor performance status, and indicate that more elderly patients may benefit from allogeneic SCT aimed at curative treatment for otherwise incurable disease. Hence, with available RIC, patient selection should be considered according to their biological age (eg performance status, current active clinical problems, past medical and surgical history) rather than chronological age. Further improvement of the conditioning, based on the aforementioned proof of principle, focusing on targeted immunotherapy rather than nonselective stronger anticancer chemoradiotherapy, may further improve our capacity to treat more effectively and more safely diseases of the elderly considered until recently incurable.
